Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03527238 · ClinicalTrials.gov registry record · Phase 2
Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
A Phase 2 study of Kidney Transplant and Liver Transplant, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 3
- Study locations
NCT03527238: Completed Phase 2 study of Kidney Transplant and Liver Transplant, sponsored by University of Florida.
NCT03527238 is a Phase 2 study of Kidney Transplant and Liver Transplant that has completed, run by University of Florida. The registered enrollment target is 62 participants, below the 1,896-participant average among 30 other Kidney Transplant trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03527238, a Phase 2 study of Kidney Transplant and Liver Transplant, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 3
- Study locations
Study Summary
Clinical trial applying Phenotypic Precision Medicine (PPM) to tacrolimus dosing in liver and/or kidney transplant recipients to show improvement in maintaining drug trough levels within the target range.
Primary Outcome
Percentage of Days Far (\> 2 ng/mL) Out of Range of Tacrolimus Target Trough Level
Conditions Studied
Interventions
- DRUG Tacrolimus
- OTHER PPM-based Computation Assisted Drug Dosing
Study Locations (3)
California
- UCLA - Los Angeles
Florida
- UF Health at the University of Florida - Gainesville
Other
- National University of Singapore - Singapore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2018-09-21 |
| Est. Completion | 2021-08-31 |
| Phase | Phase 2 |
What the finished NCT03527238 record still lists
NCT03527238 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 1,896-participant average among 30 other Kidney Transplant trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Kidney Transplant appearing as the primary indexed condition, and to 2 interventions - of which Tacrolimus is the first listed.
NCT03527238 reports a single indexed study location in California, Florida, Other.
Frequently Asked Questions
What is clinical trial NCT03527238 about?
NCT03527238 is a clinical study titled "Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine". Clinical trial applying Phenotypic Precision Medicine (PPM) to tacrolimus dosing in liver and/or kidney transplant recipients to show improvement in maintaining drug trough levels within the target range.
What is the current status of trial NCT03527238?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2018-09-21. Estimated completion is 2021-08-31.
What conditions does trial NCT03527238 study?
This clinical trial studies the following conditions: Kidney Transplant, Liver Transplant.
What interventions are being tested in trial NCT03527238?
The interventions under investigation include: Tacrolimus (DRUG), PPM-based Computation Assisted Drug Dosing (OTHER).
Who is sponsoring clinical trial NCT03527238?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03527238 being conducted?
This trial has 3 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03527238's enrollment target sits among peer trials
62 16th of 30 higher than 15 of 30 other Kidney Transplant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Transplant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Advancing Transplantation Outcomes in Children
RECRUITING · Phase 2
-
Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation
RECRUITING · Phase 2
-
Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)
RECRUITING · Phase 2
-
Sotagliflozin Safety and Tolerability Among Renal Transplant Recipients
COMPLETED · Phase 2
-
COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study
COMPLETED · Phase 2
-
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI